2 ratings / 1 average

Introduction of Rivaroxaban in an Orthopaedic Department

Alain Borgeat, MD, PhD

Rivaroxaban is a new antithrombotic drug that has been shown to provide superior efficacy to enoxaparin without increasing the risk of bleeding after major lower limb surgery. The introduction of this drug in a surgical department represents a paradigm change, since rivaroxaban is not administered preoperatively but postoperatively, and is not given subcutaneously but orally. These subtle changes require a complex process for its introduction in an orthopedic department to avoid severe complications caused by human error. This article presents the experience with this change in one hospital orthopaedic department. Adv Orthop 2010;2(3):100–5.

Return to top

RELATED ARTICLES

Antiplatelet Agents in the Treatment of ST-Segment Elevation Myocardial Infarction
Peter R Sinnaeve, MD, PhD, and Frans J Van de Werf, MD, PhD
CML Cardiology
Diabetes and Orthopaedic Surgery
Luca Dalla Paola, MD, Anna Carone, MD, Silvia Ricci, MD, and Andrea Russo, MD
Advances in Orthopaedics
Stem Cell Therapy in Orthopaedic Surgery
Chin Tat Lim, MD, and Hwan Tak Hee, MD
Advances in Orthopaedics

LATEST ARTICLES

Our most popular articles